edward lifesci set sight transcathet mitral
updat forecast estim jan
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim jan
price data jan
rate updat jan
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
last two decad demonstr
know maintain leadership innov
tissu heart valv edward remain domin forc surgic
heart valv minim invas valv therapi -- one
hottest area cardiac devic
edward done good job refocus higher-margin
product churn meaning innov effort
result impress gross margin
improv sinc becom stand-alon compani
although firm significantli smaller close competitor
abbott term sale remain global leader
core busi tissu heart valv command
global market firm maintain leadership posit
critical-car monitor equip complement heart
edward regularli engag serial acquisit
firm recent made seri purchas transcathet mitral
valv technolog order get jump next wave
innov firm remain lead edg domin
balloon-expand sapien transcateth aortic valv also
lead commerci transcathet mitral repair
replac product includ pascal cardioband edward
pois ride wave new technolog shift valv
replac transcathet approach especi
clinic data support efficaci safeti product
said still anticip potenti bump
road edward alreadi taken shot transcathet mitral
valv littl success challeng area given
heterogen condit econom behind
transcathet aortic valv replac remain less attract
surgic valv mani hospit though eas
market also becom crowd
abbott fray nonetheless think
long-term clinic trend shift toward transcathet
technolog edward sit pretti
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
spun design
manufactur market rang medic devic equip
advanc stage structur heart diseas key product includ surgic
cathet retractor monitor system use measur
patient heart function surgeri firm deriv
total sale outsid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
modestli rais fair valu estim
per share account time valu money
europ clear pascal mitral repair
cardioband mitral tricuspid use project
tmtt portfolio reach million revenu
driven product assum regulatori
clearanc food drug administr
probabl evoqu transcathet mitral
replac devic approv tavr remain
largest driver valuat assum low
midteen growth sapien revenu
reflect indic expans includ low-risk patient
importantli think edward eventu captur
subseg high-risk surgic patient
intermediate-risk patient low-risk patient
base avail clinic data expect oper
margin hold steadi around effici
gener off-set price pressur competitor enter
market edward balanc invest
support burgeon transcathet mitral tricuspid
technolog pipelin expect sapien growth
take account recent strength next-gener
launch new clinic data could sway practition
toward sapien new low-risk patient entranc
new competitor
transcathet aortic mitral tricuspid valv
franchis drive averag annual top-lin growth
edward
domest price pressur exacerb
expect new entrant emerg may need revisit
assumpt year total think
increas
compound annual
incom
base rel narrow concentr product
portfolio edward rate firm uncertainti high
competitor falter
recogn may substanti upsid patient
pool tavr expand includ intermediate-
low-risk patient addit competit europ remain
peripher
develop
transcathet mitral tricuspid devic case
sketch bull scenario abbott boston
unabl grow major tavr rival
unabl address heart-rhythm complic associ
corevalv condit would drive tavr sale
roughli billion oper margin would
hover averag annual revenu
growth adjust earn growth
scenario bring fair valu estim per
hand see share loss abbott
boston scientif along
aggress price pressur -- expect
growth transcathet aortic valv sale also assum
evoqu never receiv regulatori approv
oper margin peak assumpt
would see top-lin growth price pressur
requir invest research develop
would keep earn growth averag would
slice valuat per share
despit compet rather matur surgic heart valv
market come domin tissu
valv introduc key transcathet aortic valv
technolog sinc grown roughli billion
global market thu dig narrow moat base
intang asset compani long histori
pioneer new heart valv still highli regard
cardiac surgeon technolog advanc edward
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
wide adopt patient pool expand
includ intermediate-risk patient time trial
data amass new low-risk indic ad
anticip firm expand tavr
indic fuel growth
edward also firmli set sight tackl larger
technic challeng develop transcathet mitral valv
repair replac option estim moati
tmv market could grow billion thank
greater incid mitral valv diseas edward
work least four differ repair replac
platform firm recent receiv european
regulatori clearanc two transcathet mitral
stand behind stabl moat trend rate
edward expect continu technolog innov
help counter grow threat competit
edward global leader surgic tissu heart valv
less invas technolog put ahead
competitor similar lead edward enjoy
pioneer tavr product think edward may also carv
similar head start impress pipelin
transcathet mitral repair replac product
addit edward alreadi launch next-gener
sapien ultra edward consist improv upon
transcathet product enhanc make
even thinner easier faster use virtual
elimin sever valve-leakag complic
affect patient earlier technolog
compani success develop transcathet
mitral valv technolog think edward could
transcathet valv
everywher formid competitor
key geographi includ abbott
boston scientif establish footprint europ
compet abbott primarili mechan heart valv
boston scientif howev edward
remain heavi hitter tissu valv segment like
mani devic compani edward compet
basi technolog innov intellectu properti
close relationship physician
last decad edward focus
technolog given heart valv market jolt
develop minim invas aortic heart valv
instal cathet therebi make
procedur recoveri much easier patient current
tradit valv requir extens surgic procedur
implant mean estim half one third
elderli patient need valv replac
frail high-risk undergo surgic valv replac
edward establish leader transcathet
aortic valv franchis tavr wiht sapien product
deliv either femor arteri similar
angioplasti small hole two rib
minim invas therapi initi tap pool
aortic stenosi patient inoper high-risk
candid tradit valv surgeri technolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
boston recent launch lotu edg valv
abbott also enter next year
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
oedward effort focu effici higher-
margin product paid gross margin
increas
ocardiothorac surgeon fairli conserv
bunch like stick proven devic brand
pioneer heart valv edward continu
seen gold standard
oedward benefit age popul
experi problem heart valv
congest heart failur greater frequenc
oedward ambit diversifi
minim
invas medic technolog place firm direct
competit much larger competitor
abbott easili bid price
emerg technolog edward
oboston scientif enter tavr market
abbott like join time
oif sapien price remain high even entranc
new rival payer may limit usag transcathet
valv intermediate-risk low-risk patient
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
edward light debt leverag larg cash invest
posit give firm financi flexibl end
septemb edward major debt outstand
consist roughli million senior unsecur note
matur mean time firm sat
billion cash invest follow
recent cardiaq valtech acquisit bolster
mitral valv pipelin gross debt/ebitda stand well
time estim interest coverag
time view share repurchas like use
edward excess financi resourc time
manag indic prudent prefer make
repurchas time share look attract
valu marketplac howev recogn
edward share consist ran ahead intrins
valu opportun repurchas share attract
valuat far
million repurchas compani pay
dividend merger acquisit strategi also remain
research develop effort smaller acquisit
expand product offer
purchas
technolog edward ride high growth wave
transcathet aortic valv expect abl
easili fund growth support strateg acquisit
financi resourc cash flow unless
firm becom enamor
opportun someth view unlik
anticip major chang easili manag capit
base rel narrow concentr product
portfolio edward rate firm uncertainti
high volum edward heart valv still requir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
major surgeri implant medic industri
move toward minim invas procedur
cut recoveri time cost although edward
current enjoy duopoli transcathet aortic valv
 new competitor
horizon lotu edg devic easier
use faster use work broader rang patient
could cut sapien franchis recogn boston
prove fierc competitor cardiac
devic market clinic outcom sapien valv
much longer term yet assess durabl
product meet exceed track record
surgic valv clinician may wari use product
younger patient addit preliminari data
hint substanti portion elderli patient
popul would expir anyway independ
caus within sever year even implant
sapien valv rais question medicar
appetit reimburs expens devic put
pressur tavr manufactur demonstr
econom valu technolog edward much ride
tmtt
product -- area firm alreadi seem sever
pipelin product fail pan final edward could see
competit surgic tool busi minim
invas surgic system maker
enter cardiac surgeri market
success commerci
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
michael mussallem ceo/chairman board/
repres date owner name posit common share held report holder issuer
american fund growth fund amer
share
fund
share
fund
think edward stewardship exemplari previous
group vice presid baxter michael mussallem
ceo chairman edward sinc spin-off
offer steadi presenc helm mussallem receiv
reason compens like goal
bonu place emphasi top-lin growth free
cash flow growth net incom also taken
consider think often subject
would like see even greater detail specif
measur mussallem judg would prefer
see free cash flow gener weight heavili
net incom growth pleas edward reli
restricted-stock unit vest five year rather
stock option alon encourag mussallem
manag edward eye toward longer term
addit performance-bas restrict stock unit
determin base total sharehold return
three-year period compar index healthcar
equip compani like succession-plan
updat provid board meet ensur
board highli involv survey manag talent
potenti execut posit think firm
overal corpor govern polici well design
capital-alloc standpoint edward made
wise decis unlik larger rival edward
reli heavili serial acquisit instead
first prioriti plow resourc intern innov
kept surgic heart valv busi
leadership posit support consist
meaning innov transcathet aortic valv
portfolio one major earli acquisit edward made
percutan valv million
includ mileston payment laid
foundat edward sapien technolog addit
pvt catapult edward race enter tavr
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
market first edward might lucki
purchas mani early-stag technolog
end gutter ball nevertheless edward enjoy
strong posit categori project grow beyond
billion edward recent acquisit cardiaq
harpoon valtech bolster firm invest
transcathet mitral valv therapi even though
commerci technolog could take year
think edward strong posit pursu market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
growth chang fve oct
quarterli growth sapien transcathet aortic valv
like driven strong demand indic expans
includ patient low-risk surgic replac
incorpor optimist project sapien
sale next year outsid
longer term wasnt materi enough
bump fair valu remain confid edward
narrow econom moat abil creat meaning
innov gener econom profit
long term
find edward perform europ particularli
instruct rival launch
lotu tavr product abbott portico devic
horizon europ edward hung onto
leadership posit tavr market featur four
competitor even though second market chalk
sapien technolog merit steadi stream
improv product line substanti train
support practition center adopt
use sapien though boston domest roll-out lotu
remain earli day continu think product
garner minor share practition tri product
remain skeptic unseat sapien
quarterli sapien sale eye-pop year
year expect demand remain solid
low-risk patient opt tavr though one-tim
stock pattern support third-quart growth like
wont occur edward kept tight control
expens remain track meet bottom-lin
expect continu project robust spend
support number clinic trial includ
pivot trial pascal mitral regurgit sapien
transcathet mitral replac
transcathet mitral tricuspid technolog
area soft third quarter though disappoint
clearli overshadow unexpectedli strong
sapien perform edward expect tmtt
categori fall short million manag
origin project full year base tmtt
growth second third quarter weve estim
full-year revenu million
slow tmtt start caus concern opinion
sever reason first tmtt segment primarili
reflect earli day adopt pascal europ
pascal first major launch entir
transcathet mitral toolbox edward work
second consist edward commerci
approach previou product firm focus
provid key center practition train
support ensur favor patient outcom
critic factor lay groundwork wider spread
practition adopt later initi patient dont
well pascal therapi procedur fail go smoothli
becom much difficult increas adopt
third keep edward modu operandi firm
price pascal premium mitraclip reflect
pascal superior certain featur includ eas
use strategi edward took
initi roll sapien -- year later sapien
continu command price premium point
growth pascal revenu larg determin
quickli firm train intervent cardiologist
establish new center tavr pace expand
new center isnt necessarili smooth quarter
quarter thu expect pascal center also follow
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
perform track along full-year
project havent made chang
estim boost fair valu
estim bake optimist estim
long-term growth cash flow realiz sinc last
updat see littl chang view edward narrow
econom moat howev think worth monitor
firm stabl moat trend next month
pivot trial transcathet mitral tricuspid
get closer fruition preliminari clinic data favor
european adopt pascal cardioband robust
pleas hear transcathet aortic sapien
valv sale seem grow line procedur growth
second quarter shift saw
last year appear aggress
price corevalv edward indic lost
market share remain disciplin premium
price quarterli sapien revenu sale
respect underli basi see
littl evid rival control
launch lotu edg tavr slow sapien growth
nonetheless wouldnt surpris see practition
tri lotu next quarter boston ramp
physician train establish center
boston roll-out
met
enthusiasm still take time put dent sapien
growth view lotu edg current indic
inoper high surgic risk patient sapien
alreadi expand indic includ intermedi
risk pool expect expans encompass
low surgic risk patient second half boston
meanwhil still enrol trial intermedi risk
item caught attent quarter first
launch pascal europ run smoothli
cardioband suppli improv two tmtt
product first edward gate european
adopt give us sens devic might
perform sale remain small million
second quarter expect acceler edward
cardiologist train new center establish
next month particularli interest pascal
consid rival abbott recent success mitraclip
saw growth second quarter edward
expect begin enrol pivot pascal trial
function mitral regurgit end year
market
though cardioband struggl manufactur
challeng constrain suppli edward
shift manufactur site improv
situat unlik pascal cardioband first
new direct annuloplasti devic enter market
demonstr strong eas use think could hold
potenti pascal could provid
durabl repair annulu especi function mitral
condit put particular stress anatomi mitral
earliest
discontinu self-expand centera tavr product
market europ stop develop
forma devic tricuspid diseas order focu
resourc pascal sapien mitral use
cardioband although medic technolog busi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
often one enough shot goal seem
edward shot goal perhap exceed firm
bandwidth success develop commerci
way enviabl problem
nevertheless look favor manag decis
alloc resourc deliber support strongest
candid potenti underscor
make apolog make concentr bet
differenti superior technolog back
appropri resourc
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
